ArticlePharmacological reports : PR2020
Ciprofloxacin and moxifloxacin could interact with SARS-CoV-2 protease: preliminary in silico analysis.
Article in Pharmacological reports : PR, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 33 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
33 citing papers in PubMed, 1 synthesis or guideline pooled it, 78 citations in OpenAlex.
- COVID-19 in comorbid chronic diseased patients, pregnant and lactating women: pathophysiology, available drug treatment, and the most suitable protocol regimen in each group.Inflammopharmacology · 2025Pooled it
- Development and validation of HPLC-FLD method for simultaneous determination of ternary therapy used for COVID-19 in plasma samples.Scientific reports · 2026Article
- Trends of ciprofloxacin use in Kazakhstan, impacts of COVID-19, and strategies for AMR control.Scientific reports · 2025Article
- High sensitivity determination of ciprofloxacin by fluorescence sensor based on encapsulation of coumarin derivative with ZIF-8.Mikrochimica acta · 2025Article
- Article
- The impact of the COVID-19 pandemic on antimicrobial usage: an international patient-level cohort study.JAC-antimicrobial resistance · 2025Article
- Repositioning of Antibiotics in the Treatment of Viral Infections.Current microbiology · 2024Review
- Exploration of Specific Fluoroquinolone Interaction with SARS-CoV-2 Main Protease (Mpro) to Battle COVID-19: DFT, Molecular Docking, ADME and Cardiotoxicity Studies.Molecules (Basel, Switzerland) · 2024Article
- Article
- Increasing Fluroquinolone Susceptibility and Genetic Diversity of ESBL-ProducingAntibiotics (Basel, Switzerland) · 2024Article
- Advancements in Synthetic Strategies and Biological Effects of Ciprofloxacin Derivatives: A Review.International journal of molecular sciences · 2024Review
- Immunomodulatory Effects of Fluoroquinolones in Community-Acquired Pneumonia-Associated Acute Respiratory Distress Syndrome.Biomedicines · 2024Review
- Drug-Induced Acute Pancreatitis in Hospitalized COVID-19 Patients.Diagnostics (Basel, Switzerland) · 2023Review
- The Association between Previous Antibiotic Consumption and SARS-CoV-2 Infection: A Population-Based Case-Control Study.Antibiotics (Basel, Switzerland) · 2023Article
- Magic bullets, magic shields, and antimicrobials in between.Pharmaceutical science advances · 2023Review
- Article
- In silico prediction of potential inhibitors for SARS-CoV-2 Omicron variant using molecular docking and dynamics simulation-based drug repurposing.Journal of molecular modeling · 2023Article
- Novel ciprofloxacin and norfloxacin-tetrazole hybrids as potential antibacterial and antiviral agents: TargetingJournal of molecular structure · 2023Article
- An experimental in silico study on COVID-19: Response of neutrophil-related genes to antibiotics.Health science reports · 2022Article
- In vitro inhibition and molecular docking of a new ciprofloxacin-chalcone against SARS-CoV-2 main protease.Fundamental & clinical pharmacology · 2022Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors at 1 institution in 1 country.
Funding
Abstract
backgroundA large body of research has focused on fluoroquinolones. It was shown that this class of synthetic antibiotics could possess antiviral activity as a broad range of anti-infective activities. Based on these findings, we have undertaken in silico molecular docking study to demonstrate, for the first time, the principle for the potential evidence pointing ciprofloxacin and moxifloxacin ability to interact with COVID-19 Main Protease.
methodsIn silico molecular docking and molecular dynamics techniques were applied to assess the potential for ciprofloxacin and moxifloxacin interaction with COVID-19 Main Protease (M
resultsWe revealed that the tested antibiotics exert strong capacity for binding to COVID-19 Main Protease (M
conclusionsHere, we have demonstrated for the first time that ciprofloxacin and moxifloxacin may interact with COVID-19 Main Protease (M
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.